Board of directors

Nicole Onetto, M.D.

Member of the board of directors

Nationality: Canadian and French | Year of Birth: 1953

Nicole Onetto, M.D., has been a member of the board
since 2017. She is also a member of the compensation committee. She is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.

Ms. Onetto is an independent consultant in oncology, drug development and translational research. She was deputy director & chief scientific officer at the Ontario Institute for Cancer Research from 2009 to 2016. From 2005 to 2009 she was senior vice president and chief medical officer at ZymoGenetics Inc. From 2002 to 2005, she served at OSI Pharmaceuticals, Inc., first as executive vice president Oncology, and then as chief medical officer and executive vice president. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc.

Ms. Onetto is a member of the board of Bolt Biotherapeutics, Inc. and of CDR-Life AG.  
She served as member of the board of ImmunoGen Inc. from 2005 to 2016, of YM BioSciences Inc. from 2014 to 2015, of Sierra Oncology, Inc. from 2015 to 2019, of NBE-Therapeutics AG from 2017 to January 2021, and of Viracta Therapeutics, Inc. (previously Sunesis Pharmaceuticals, Inc.) from 2019 to
February 2023.

Ms. Onetto holds a doctor of medicine from the University of Paris and a master of pharmacology from the University of Montréal.